- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
Background: TrkC (tropomyosin receptor kinase C) or neurotrophin-tyrosine kinase receptor type 3 (NTRK3) is a member of the Trk family of neurotrophin receptors. Structurally, TKR proteins share a similar design with an extracellular ligand binding domain, a transmembrane domain, and an intracellular kinase domain. Upon binding of its ligand NTF3/neurotrophin-3, TRKc autophosphorylates and activates different signaling pathways, e.g. the phosphatidylinositol 3-kinase/AKT and the MAPK pathways and thus promotes neuronal differentiation and survival. TRK fusions with other proteins, TRK protein amplification as well as alternative splicing events have been well-established as oncogenic events in specific malignancies, including glioblastoma, papillary thyroid carcinoma, and secretory breast carcinomas.
Recombinant Human TRK-C (neurotrophic tyrosine kinase, receptor, type 3 / tyrosine kinase receptor C), protein kinase domain (amino acids V510-G825), recombinant and active enzyme, N-terminal GST-HIS6 fusion protein with a Thrombin and 3C cleavage site, expressed in Sf9 insect cells
Theoretical MW : 64.870 kDa (fusion proteins)
Expression system: Baculovirus infected Sf9 cells
Purification: GST-Affinity Chromatography
Activation: in vitro autoactivation
Storage buffer: 50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT, 15 mM reduced glutathione, 20% glycerol
Protein concentration: 0.085 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MSFC membrane
Specific activity : 35.000 pmol/mg min
Entrez Gene ID 4916
UniProtKB Q16288
Ordering information: shipped on dry ice
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. (2017) “Targeting TRK family proteins in cancer.” Pharmacol Ther.;173:58-66.
Lange AM, Lo HW. (2018) “Inhibiting TRK Proteins in Clinical Cancer Therapy.” Cancers (Basel). 2018 Apr 4;10(4).
Lawn S, Krishna N, Pisklakova A, Qu X, Fenstermacher DA, Fournier M, Vrionis FD, Tran N5, Chan JA, Kenchappa RS, Forsyth PA. (2015) “Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells.” J Biol Chem. 2015 Feb 6;290(6):3814-24.
Welcome Login
Contact us
Follow us